Patents by Inventor Tongtong Xue

Tongtong Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11903948
    Abstract: Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: February 20, 2024
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Zhenwei Miao, Jing Wang, Gang Chen, Yan Qing, Tong Zhu, Liang Xiao, Hong Zhang, Qiuyan Yang, Dylan Dalun Deng, Liping Liu, Hong Zeng, Li Yin, Qifeng Shi, Hongmei Song, Xi Zhao, Lichun Wang, Jingyi Wang
  • Patent number: 11884725
    Abstract: Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: January 30, 2024
    Assignee: Ampsource Biopharma Shanghai Inc.
    Inventors: Qiang Li, Tongtong Xue, Yuncheng Zheng, Liang Xiao, Dengnian Liu, Jianyu Sun, Jiangjiang Hu, Xinlu Ma, Kangyong Zhu, Yuanli Li
  • Publication number: 20230357259
    Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.
    Type: Application
    Filed: January 17, 2023
    Publication date: November 9, 2023
    Inventors: Jiaqiang CAI, Shuai SONG, Tongtong XUE, Liang XIAO, Hanwen DENG, Qiang TIAN, Jing WANG, Dengnian LIU, Liping LIU, Haimin YU, Zhouning YANG, Xu CAO, Guoqing ZHONG, Lichun WANG, Jingyi WANG
  • Publication number: 20230338565
    Abstract: Related is an anti-CLDN 18.2 antibody-drug conjugate, preparation method and use thereof. The antibody-drug conjugate and the composition thereof is capable of effectively binding CLDN 18.2 and inhibiting the growth of Claudin 18.2 positive tumors. Further related is a pharmaceutical composition comprising the antibody-drug conjugate or the composition, and use of the pharmaceutical composition in the preparation of a medicament for preventing and/or treating tumors.
    Type: Application
    Filed: May 12, 2021
    Publication date: October 26, 2023
    Inventors: Liang XIAO, Tongtong XUE, Jingyi WANG, Cheng WANG, Dengnian LIU, Qiang TIAN, Shuai SONG
  • Publication number: 20230303562
    Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: September 28, 2023
    Inventors: Qiang TIAN, Yitao ZHANG, Xiaoling JIANG, Chunchi LIU, Bingqiang KANG, Ruihong LIU, Hongmei SONG, Tongtong XUE, Jingyi WANG
  • Publication number: 20230295174
    Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.
    Type: Application
    Filed: July 23, 2021
    Publication date: September 21, 2023
    Inventors: Zheng Gong, Hongming Li, Shidong Yi, Long Li, Tianming Wang, Pingyun Chen, Chengxi Yang, Tao Wang, Yaoyao Song, Jiangfeng Zhou, Yufeng Liang, Zhonghui Chen, Qiang Tian, Hongmei Song, Tongtong Xue, Jingyi Wang
  • Publication number: 20230293536
    Abstract: The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, and use of the conjugate.
    Type: Application
    Filed: May 26, 2023
    Publication date: September 21, 2023
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG
  • Publication number: 20230287122
    Abstract: Provided is an anti-PD-L1 antibody preparation, including an anti-PD-L1 antibody, a buffer solution and sodium chloride, without added sugars and/or sugar alcohols. Also provided is the use of the anti-PD-L1 antibody preparation in the preparation of drugs for preventing and/or treating and/or adjuvant treating and/or diagnosing a tumor or anemia.
    Type: Application
    Filed: November 26, 2019
    Publication date: September 14, 2023
    Applicants: HARBOUR BIOMED THERAPEUTICS LIMITED, SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Liang XIAO, Liping DENG, Haiyu HUANG, Qigang LIU, Liping LIU, Dalton GUO, Tongtong XUE, Jingyi WANG
  • Publication number: 20230203178
    Abstract: Provided are a chimeric antigen receptor (CAR) or CAR construct containing antibodies against BCMA and CD19, a nucleic acid molecule encoding the CAR or CAR construct, a modified immune cell, and a method for preparing the immune cell. The CAR or CAR construct and the modified immune cell are used for the prevention and/or treatment of B cell related conditions (e.g., B cell and plasma cell related malignant tumors or autoimmune diseases (such as systemic lupus erythematosus)), and can effectively avoid target escape and prevent the recurrence of multiple myeloma.
    Type: Application
    Filed: June 25, 2021
    Publication date: June 29, 2023
    Inventors: Jianhui CHANG, Yanlin ZHU, Guangjun JING, Jingyi WANG, Jiangman WANG, Zhenzhen CAI, Panyan HOU, Liang XIAO, Tongtong XUE, Xiaodong WANG
  • Publication number: 20230192840
    Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.
    Type: Application
    Filed: December 19, 2019
    Publication date: June 22, 2023
    Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., KLUS PHARMA INC.
    Inventors: Haijun TIAN, Sujun DENG, Chunxia ZHAO, Hong LI, Dengnian LIU, Hu LONG, Cheng WANG, Liang XIAO, Tongtong XUE, Jingyi WANG
  • Patent number: 11655295
    Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: May 23, 2023
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Qiang Li, Liang Xiao, Yuncheng Zheng, Dengnian Liu, Si Chen, Yan Hu, Lichun Wang, Jingyi Wang
  • Publication number: 20220363781
    Abstract: Related are an anti-TSLP antibody or an antigen-binding fragment thereof, nucleic acid molecules coding the same, and a method for preparing the same. The anti-TSLP antibody or the antigen-binding fragment thereof have high affinity to TSLP, capable of effectively binding with TSLP and blocking the proliferative effect of TSLP with respect to Ba/F3-hTSLPR-hIL7R? cells, and blocking the capability of TSLP in activating and secreting cytokines with respect to PBMC. At the same time, further related are a medicinal composition comprising the antibody or the antigen-binding fragment thereof, and uses of the composition in preparing a medicament for preventing and/or treating asthma, allergic inflammation, an allergic reaction or autoimmune disease.
    Type: Application
    Filed: December 8, 2020
    Publication date: November 17, 2022
    Applicants: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD., Harbour Biomed (Suzhou) Co., Ltd.
    Inventors: Liang XIAO, Jinqiu HE, Tongtong XUE, Hongshui LIU, Jingyi WANG, Hongzhuan GU, Shuntao LUO, Yiping RONG, Dengnian LIU, Yun HE
  • Patent number: 11421029
    Abstract: Provided are a recombinant bispecific antibody against CTLA-4 and PDL-1, a nucleic acid molecule for encoding the antibody, a vector and a host cell comprising the nucleic acid molecule, and a method for preparing the antibody. Also provided are a pharmaceutical composition comprising the bispecific antibody, and usage of the bispecific antibody in preparation of the pharmaceutical composition.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: August 23, 2022
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong Xue, Liang Xiao, Dengnian Liu, Hu Long, Jiangjiang Hu, Yamin Cui, Xiaoxi Yuan, Lichun Wang, Jingyi Wang
  • Publication number: 20220220075
    Abstract: The present application relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and uses of the solid form in preparing a medicament for treating or preventing peroxisome proliferator-activated receptor (PPAR)-related diseases such as nonalcoholic fatty liver disease (NAFLD).
    Type: Application
    Filed: May 21, 2020
    Publication date: July 14, 2022
    Applicant: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    Inventors: Shidong YI, Tianming WANG, Zhuan WU, Long LI, Chengxi YANG, Zhiquan SONG, Dong LONG, Qiang TIAN, Hongmei SONG, Tongtong XUE, Jingyi WANG
  • Publication number: 20220162338
    Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.
    Type: Application
    Filed: April 6, 2020
    Publication date: May 26, 2022
    Inventors: Haijun TIAN, Dengnian LIU, Sujun DENG, Marc Peter CIUCCI, Cheng WANG, Yong ZHENG, Liang XIAO, Tongtong XUE, Jingyi WANG
  • Publication number: 20220162199
    Abstract: A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.
    Type: Application
    Filed: April 20, 2020
    Publication date: May 26, 2022
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jinming LIU, Yun REN, Qiang TIAN, Hongmei SONG, Tongtong XUE, Jingyi WANG
  • Publication number: 20220144847
    Abstract: The present disclosure relates to a heterocyclic compound, a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention is represented by formula (I), and used for preventing or treating a disease or condition related to RET activity.
    Type: Application
    Filed: February 11, 2020
    Publication date: May 12, 2022
    Inventors: Zhonghui Chen, Shuangshuang Duan, Guiying Li, Runfeng Han, Qizheng Sun, Liandong Jing, Xiaojun Han, Qiang Tian, Hongmei Song, Tongtong Xue, Jingyi Wang
  • Publication number: 20220056043
    Abstract: The present invention relates to a nitrogen-containing fused ring compound, a preparation method and use thereof. Specifically, the present invention relates to a compound having the structure of Formula (X), a stereoisomer, tautomer or mixture thereof, a pharmaceutically acceptable salt, co-crystal, polymorph or solvate thereof, or a stable isotope derivative, metabolite or prodrug thereof. The compound of the invention may have the structure of Formula (I) or Formula (II). These compounds are useful for the treatment of an abnormal cell proliferation disease (e.g., cancer).
    Type: Application
    Filed: February 10, 2020
    Publication date: February 24, 2022
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: GUIYING LI, Zejin YOU, Yun HE, Qiang TIAN, Hongmei SONG, Tongtong XUE, Jingyi WANG
  • Publication number: 20220017483
    Abstract: Disclosed by the present invention are an aminopyridine compound, a preparation method therefor and a use thereof, which are specifically an aminopyridine compound represented by formula (I), a pharmaceutical composition containing same, a preparation method therefor and a use thereof in preventing or treating diseases related to adenosine A2a receptors.
    Type: Application
    Filed: December 19, 2019
    Publication date: January 20, 2022
    Applicant: SICHUAN-KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD
    Inventors: Jinming LIU, Ting HE, Jiaqiang CAI, Zhenewn DONG, Qiang TIAN, Hongmei SONG, Tongtong XUE, Lichun WANG, Jingyi WANG
  • Publication number: 20220008553
    Abstract: Provided is a method for the prophylaxis or treatment of cancer, comprising administering to a patient in need thereof an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing, wherein A, X, Y, L, D and a are as defined herein.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 13, 2022
    Applicant: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Tongtong XUE, Zhenwei MIAO, Jing WANG, Gang CHEN, Yan QING, Tong ZHU, Liang XIAO, Hong ZHANG, Qiuyan YANG, Dylan Dalun DENG, Liping LIU, Hong ZENG, Li YIN, Qifeng SHI, Hongmei SONG, Xi ZHAO, Lichun WANG, Jingyi WANG